Opthea Ltd. ADR (OPT) News

Opthea Ltd. ADR (OPT): $7.00

0.09 (+1.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

Filter OPT News Items

OPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OPT News Highlights

  • For OPT, its 30 day story count is now at 4.
  • Over the past 5 days, the trend for OPT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • AMD, EYE and AGE are the most mentioned tickers in articles about OPT.

Latest OPT News From Around the Web

Below are the latest news stories about Opthea Ltd that investors may wish to consider to help them evaluate OPT as an investment opportunity.

Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration

Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). Sixty-six participants (18%) with Polypoidal Choroidal Vasculopathy (PCV) out of a total stud

Yahoo | February 14, 2022

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV – a subtype of AMD, prevalent among Asian populations with high unmet medical need MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea L

Yahoo | February 14, 2022

Opthea To Present at SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. The presentation will be available beginning Thursday, February 1

Yahoo | February 10, 2022

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022. Professor Gemmy Cheung will present data from patients with polypoidal choroidal vasculo

Yahoo | February 9, 2022

Opthea Receives A$6.6 m R&D Tax Incentive

MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it has received a A$6.6 million (US$4.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2020/2021 financial year, and represents the amount di

Yahoo | January 24, 2022

Is Opthea Limited (ASX:OPT) Popular Amongst Institutions?

If you want to know who really controls Opthea Limited ( ASX:OPT ), then you'll have to look at the makeup of its share...

Yahoo | January 10, 2022

Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference

MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the H.C. Wainwright BIOCONNECT Conference, being held virtually from January 10-13, 2022. The pre-recorded presentation will be available beginning Monday, January 10, at 7:00 am ET (11:00 p

Yahoo | January 4, 2022

Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD

MELBOURNE, Australia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Ms. Judith Robertson as the Company’s first Chief Commercial Officer (CCO), effective 1 January 2022. Concurrently with this appointment, Ms. Robertson has stepped down as a non-executive member of the Opthea Board of Directors, a pos

Yahoo | January 3, 2022

Opthea Granted Chinese Patent Covering OPT-302

MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the grant of Chinese Patent Number (CN) 106414487 B covering OPT-302, its soluble VEGFR-3 “trap” molecule currently being investigated in two global Phase 3 registrational clinical trials, ShORE (Study of OPT-302 in combination with Ranibizumab) and COA

Yahoo | October 26, 2021

Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD

MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that the first clinical trial sites in the Asia-Pacific region are now open for patient enrollment into the OPT-302 Phase 3 pivotal clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD). The clinical trial sites, locate

Yahoo | October 19, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.0049 seconds.